Cargando…

CSF Cholinergic Index, a New Biomeasure of Treatment Effect in Patients With Alzheimer’s Disease

Alzheimer’s disease (AD) is a progressive disease with early degeneration of the central cholinergic neurons. Currently, three of four AD drugs act by inhibiting the acetylcholine (ACh) degrading enzyme, acetylcholinesterase (AChE). Efficacy of these drugs depends on available amount of ACh, which i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Karami, Azadeh, Eriksdotter, Maria, Kadir, Ahmadul, Almkvist, Ove, Nordberg, Agneta, Darreh-Shori, Taher
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6798072/ https://www.ncbi.nlm.nih.gov/pubmed/31680850 http://dx.doi.org/10.3389/fnmol.2019.00239

Ejemplares similares

CSF and Plasma Cholinergic Markers in Patients With Cognitive Impairment
por: Karami, Azadeh, et al.
Publicado: (2021)

Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer’s disease
por: Kadir, Ahmadul, et al.
Publicado: (2011)

Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimer’s disease patients: application of a second-generation encapsulated cell biodelivery device
por: Eyjolfsdottir, Helga, et al.
Publicado: (2016)

Fast Alpha Activity in EEG of Patients With Alzheimer’s Disease Is Paralleled by Changes in Cognition and Cholinergic Markers During Encapsulated Cell Biodelivery of Nerve Growth Factor
por: Eyjolfsdottir, Helga, et al.
Publicado: (2022)

Homomeric and Heteromeric Aβ Species Exist in Human Brain and CSF Regardless of Alzheimer’s Disease Status and Risk Genotype
por: Lana, Erica, et al.
Publicado: (2019)

Amyloid-β peptides act as allosteric modulators of cholinergic signalling through formation of soluble BAβACs
por: Kumar, Rajnish, et al.
Publicado: (2016)

Increased Endogenous GDNF in Mice Protects Against Age-Related Decline in Neuronal Cholinergic Markers
por: Mitra, Sumonto, et al.
Publicado: (2021)

Soluble Aβ42 Acts as Allosteric Activator of the Core Cholinergic Enzyme Choline Acetyltransferase
por: Kumar, Amit, et al.
Publicado: (2018)

Increased Active OMI/HTRA2 Serine Protease Displays a Positive Correlation with Cholinergic Alterations in the Alzheimer’s Disease Brain
por: Darreh-Shori, Taher, et al.
Publicado: (2018)

A biomarker-validated time scale in years of disease progression has identified early- and late-onset subgroups in sporadic Alzheimer’s disease
por: Almkvist, Ove, et al.
Publicado: (2023)

Visual hallucinations in Alzheimer's disease do not seem to be associated with chronic hypoperfusion of to visual processing areas V2 and V3 but may be associated with reduced cholinergic input to these areas
por: Sinclair, Lindsey Isla, et al.
Publicado: (2019)

Phenotypic Displays of Cholinergic Enzymes Associate With Markers of Inflammation, Neurofibrillary Tangles, and Neurodegeneration in Pre- and Early Symptomatic Dementia Subjects
por: Teitsdottir, Unnur D., et al.
Publicado: (2022)

Regulated Extracellular Choline Acetyltransferase Activity— The Plausible Missing Link of the Distant Action of Acetylcholine in the Cholinergic Anti-Inflammatory Pathway
por: Vijayaraghavan, Swetha, et al.
Publicado: (2013)

Fibrillar β-amyloid 1-42 alters cytokine secretion, cholinergic signalling and neuronal differentiation
por: Malmsten, Linn, et al.
Publicado: (2014)

Feasibility and therapeutical potential of local intracerebral encapsulated cell biodelivery of BDNF to App(NL−G−F) knock-in Alzheimer mice
por: Tambaro, Simone, et al.
Publicado: (2023)

Biomarkers in Alzheimer's Disease and Lewy Body Disorders with Dementia
por: Leyhe, Thomas, et al.
Publicado: (2013)

Practice effects in cognitive assessments three years later in non-carriers but not in symptom-free mutation carriers of autosomal-dominant Alzheimer's disease: Exemplifying procedural learning and memory?
por: Almkvist, Ove, et al.
Publicado: (2022)

Regional tau deposition measured by [(18)F]THK5317 positron emission tomography is associated to cognition via glucose metabolism in Alzheimer’s disease
por: Saint-Aubert, Laure, et al.
Publicado: (2016)

Oral microbial communities in children, caregivers, and associations with salivary biomeasures and environmental tobacco smoke exposure
por: Rothman, Jason A., et al.
Publicado: (2023)

Novel ligands of Choline Acetyltransferase designed by in silico molecular docking, hologram QSAR and lead optimization
por: Kumar, Rajnish, et al.
Publicado: (2016)

The effects of different familial Alzheimer’s disease mutations on APP processing in vivo
por: Thordardottir, Steinunn, et al.
Publicado: (2017)

Discovery of novel choline acetyltransferase inhibitors using structure-based virtual screening
por: Kumar, Rajnish, et al.
Publicado: (2017)

Reduced penetrance of the PSEN1 H163Y autosomal dominant Alzheimer mutation: a 22-year follow-up study
por: Thordardottir, Steinunn, et al.
Publicado: (2018)

Association of glial and neuronal degeneration markers with Alzheimer’s disease cerebrospinal fluid profile and cognitive functions
por: Teitsdottir, Unnur D., et al.
Publicado: (2020)

Clinical impact of (18)F-FDG-PET among memory clinic patients with uncertain diagnosis
por: Perini, Giulia, et al.
Publicado: (2020)

Cortical microstructural correlates of astrocytosis in autosomal-dominant Alzheimer disease
por: Vilaplana, Eduard, et al.
Publicado: (2020)

Allosteric Binding Sites of Aβ Peptides on the Acetylcholine Synthesizing Enzyme ChAT as Deduced by In Silico Molecular Modeling
por: Baidya, Anurag TK, et al.
Publicado: (2022)

Early astrocytosis in autosomal dominant Alzheimer’s disease measured in vivo by multi-tracer positron emission tomography
por: Schöll, Michael, et al.
Publicado: (2015)

Targeting Beta-Amyloid at the CSF: A New Therapeutic Strategy in Alzheimer’s Disease
por: Menendez-Gonzalez, Manuel, et al.
Publicado: (2018)

Imaging in-vivo tau pathology in Alzheimer’s disease with THK5317 PET in a multimodal paradigm
por: Chiotis, Konstantinos, et al.
Publicado: (2016)

Neural Stem Cell Transplant-Induced Effect on Neurogenesis and Cognition in Alzheimer Tg2576 Mice Is Inhibited by Concomitant Treatment with Amyloid-Lowering or Cholinergic α7 Nicotinic Receptor Drugs
por: Lilja, Anna M., et al.
Publicado: (2015)

The APOE ε4 Allele Affects Cognitive Functions Differently in Carriers of APP Mutations Compared to Carriers of PSEN1 Mutations in Autosomal-Dominant Alzheimer’s Disease
por: Almkvist, Ove, et al.
Publicado: (2021)

New Insights Into Cholinergic Neuron Diversity
por: Ahmed, Noorya Yasmin, et al.
Publicado: (2019)

Basal Forebrain Cholinergic Neurons: Linking Down Syndrome and Alzheimer’s Disease
por: Martinez, Jose L., et al.
Publicado: (2021)

Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer’s disease
por: Rodriguez-Vieitez, Elena, et al.
Publicado: (2016)

Tau PET imaging in neurodegenerative tauopathies—still a challenge
por: Leuzy, Antoine, et al.
Publicado: (2019)

CSF metabolites associated with biomarkers of Alzheimer’s disease pathology
por: Dong, Ruocheng, et al.
Publicado: (2023)

Innovative Therapy for Alzheimer’s Disease-With Focus on Biodelivery of NGF
por: Mitra, Sumonto, et al.
Publicado: (2019)

Corrigendum: Basal Forebrain Cholinergic Neurons: Linking Down Syndrome and Alzheimer's Disease
por: Martinez, Jose L., et al.
Publicado: (2021)

Transmembrane Amyloid-Related Proteins in CSF as Potential Biomarkers for Alzheimer’s Disease
por: Lopez-Font, Inmaculada, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_h18n9jpu4ikgi7eql9301lije1